Oxford Biomedica notes Axovant’s positive six-month follow-up from second cohort of SUNRISE-PD Phase 2 trial of AXO-Lenti-PD

Joey Cohen
Medication Adherence

Pat Purcell
Meeting Engagement

Matthew Durham
Omnidynamic Marketing

Amy Giles
Increasing Engagement

Frank Burrell
Scientific Storytelling

Bud Bilanich
Success Coach

Matt Turner
Patient Affordability

Brenda Snow
Authentic Patient Voice

Daniel Sontupe
Market Access

Paul Theisen
Patient Acquisition

Liz Kane
Impactful Strategy

Stacey Gandler
Brand Nourishment

David Linetsky
Point-of-Care Marketing

Suma Ramadas, PhD
Medical Affairs